Current Medical Research and Opinion最新文献

{"title":"Variation in follow-up care after a new diagnosis of memory loss or cognitive impairment in a major health system.","authors":"Sandra Darling, Elizabeth R Pfoh, Ava Rezaee, Jordan Alpert, Ardeshir Hashmi, Kathryn A Martinez","doi":"10.1080/03007995.2025.2530735","DOIUrl":"10.1080/03007995.2025.2530735","url":null,"abstract":"<p><strong>Objective: </strong>Patterns of follow-up care after a new diagnosis of memory loss or cognitive impairment among primary care patients are not well-characterized. We described factors associated with diagnosis and follow-up type.</p><p><strong>Methods: </strong>This is an observational study using electronic health record data, including patients aged ≥40 years newly diagnosed with memory loss or cognitive impairment <i>via</i> primary care of a major health system in Northeast Ohio and Florida. We assessed differences in the odds of diagnosis of memory loss versus cognitive impairment. We then characterized follow-up care as: 1) medication, 2) labs, or 3) imaging, and 4) any follow-up type. We used mixed effects logistic regression to estimate the odds of follow-up care in four models, adjusting to patient factors, region, and diagnosis type.</p><p><strong>Results: </strong>Of 21,854 patients, 84% were diagnosed with memory loss and 16% were diagnosed with cognitive impairment. Black patients (versus White) had higher odds of being diagnosed with cognitive impairment versus memory loss. Overall, 49.2% received any follow-up care; 39.7% received labs, 16.7% received imaging, and 5.4% medication. Versus those diagnosed with memory loss, patients diagnosed with cognitive impairment had lower odds of any follow-up (aOR:0.74; 95%CI:0.67-0.81), lower odds of lab orders (aOR:0.70; 95%CI:0.60-0.83), but higher odds of medication (aOR:1.65; 95%CI:1.34-2.04). Compared to patients seen in Ohio, those in Florida had lower odds of any follow-up (aOR:0.56; 95%CI:0.47-0.67).</p><p><strong>Conclusions: </strong>Diagnosis type varied by some non-clinical factors and this was associated with follow-up care. Standardization of initial diagnostic and follow-up approach is warranted.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-8"},"PeriodicalIF":2.4,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Why wastewater-based epidemiology must tackle noncommunicable diseases.","authors":"Patrick M D'Aoust","doi":"10.1080/03007995.2025.2529991","DOIUrl":"10.1080/03007995.2025.2529991","url":null,"abstract":"<p><p>The global wastewater-based epidemiology (WBE) landscape has primarily concentrated on high-profile diseases, creating a narrow scope of application. However, there's a significant and significant untapped potential in using WBE to address chronic and noncommunicable diseases (NCDs), particularly in developing nations. NCDs, including heart disease and diabetes, now significantly impact low- and middle-income nations, straining their healthcare systems and economies. WBE offers a cost-effective, real-time health monitoring solution and presents a real opportunity for change in global research policy focus to hone into these diseases. By prioritizing research on the detection of chronic illness health markers in wastewater, WBE has the potential to provide accurate community-level health data and guide equitable resource allocation, addressing both high-profile infectious diseases and NCDs simultaneously. However, the potential of WBE in addressing NCDs remains largely untapped by the research community. Effective implementation requires the development of standardized methodologies, effective ethical frameworks, and robust international cooperation. This approach is essential to address the silent epidemic of NCDs effectively and ensure that developing nations are equipped with the tools necessary for sustainable healthcare management and evidence-based policymaking.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-5"},"PeriodicalIF":2.4,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generalized anxiety disorder: epidemiology, burden, and comorbid depression.","authors":"Annie Druet-Cabanac, Jessica Azzi, Marco Lucchino, Virginie Simon, Lucile Offredo, Jean-Baptiste Briere, Sean Hood","doi":"10.1080/03007995.2025.2529974","DOIUrl":"10.1080/03007995.2025.2529974","url":null,"abstract":"<p><strong>Objective: </strong>Generalized anxiety disorder (GAD) is a common long-term psychiatric disorder with varying prevalence in epidemiological studies. The burden of GAD is high and associated risk factors are not well documented in the general population.</p><p><strong>Methods: </strong>This observational retrospective study of US adult patients with GAD used Optum's de-identified Clinformatics Data Mart Database to explore epidemiology, patient characteristics, risk factors, and disease burden. Adults with GAD were matched with a control general population.</p><p><strong>Results: </strong>A total of 1,086,618 US patients with GAD were included: mean patient age was 49.4 ± 19.1 years and 66.5% were female. Incidence of GAD increased from 0.8% in 2012 to 2.4% in 2022. One-year prevalence of GAD increased from 2.1% in 2012 to 7.4% in 2022. Individuals with GAD utilized healthcare resources more frequently than the matched control population. Retrospectively-assessed risk factors most associated with GAD were pre-existing major depressive disorder (odds ratio [OR] 5.06; 95% confidence interval [CI]: 5.03, 5.08; <i>p</i> < 0.001), family problems (OR 2.83 95% CI: 2.76, 2.89; <i>p</i> < 0.001), SARS-CoV-2 infection (OR 2.53; 95% CI: 2.48, 2.57; <i>p</i> < 0.001), employment difficulties (OR 2.48; 95% CI: 2.36, 2.60; <i>p</i> < 0.01), and attention deficit hyperactivity disorder (OR 2.19; 95% CI: 2.17, 2.21; <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Risk factors, particularly depressive symptoms, should be acknowledged during the diagnosis and management of patients with GAD to support optimal clinical outcomes.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-12"},"PeriodicalIF":2.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of moderate-to-severe ulcerative colitis and Crohn's disease on sexual activity: United States and European patient perspectives from the communicating needs and features of IBD experiences (CONFIDE) survey.","authors":"Marla C Dubinsky, Alison Potts Bleakman, Stefan Schreiber, David T Rubin, Remo Panaccione, Toshifumi Hibi, Cem Kayhan, Theresa Hunter Gibble, Eoin J Flynn, Angelo D Favia, Tommaso Panni, Christian Atkinson, Sonal Saxena, Simon Travis","doi":"10.1080/03007995.2025.2530736","DOIUrl":"https://doi.org/10.1080/03007995.2025.2530736","url":null,"abstract":"<p><strong>Background: </strong>Ulcerative colitis (UC) and Crohn's disease (CD) negatively affect patients' quality of life, and their impact on patients' sexual health is rarely addressed. This study assessed the impact of moderate-to-severe UC and CD on sexual activity using United States (US) and European data from the Communicating Needs and Features of IBD Experiences (CONFIDE) survey.</p><p><strong>Methods: </strong>Online, quantitative, cross-sectional surveys were conducted among patients with moderate-to-severe UC or CD and health care professionals (HCPs). Moderate-to-severe UC or CD were defined using criteria based on previous treatment, steroid use, and/or hospitalization. The surveys were developed with input from HCPs and patient advisors and included questions on demographics, UC- or CD-related symptoms, and the impact of UC or CD on sexual health. Patients were asked whether they had avoided/decreased sexual activity in the past 3 months and their UC- or CD-related reasons. Patients and HCPs rated levels of impact of UC or CD on sex life/sexual intimacy and patients rated how bowel urgency interferes with their relationship with spouse/partner. Additionally, questions assessing the psychosocial health of patients and identifying gaps and barriers in HCP-patient communication were also included. Descriptive statistics were used to summarize the data.</p><p><strong>Results: </strong>Surveys were completed by 200 US and 556 European patients with UC and 215 US and 547 European patients with CD. Of these, most US (UC: 63%, CD: 69%) and European (UC: 53%, CD: 56%) patients reported avoiding or decreasing sexual activity due to UC or CD in the past 3 months; however, the proportion was significantly greater among US patients (P < 0.05). Among patients with UC, significantly greater proportion of female patients reported altered sexual activity due to their disease. A similar proportion of male and female patients with CD reported impaired sexual activity. Most common UC-related reasons for avoidance of sexual activity were bowel urgency among US patients and fear of faecal seepage among European patients. Among patients with CD, the most common reason was fear of bowel urgency-related accidents in both US and European patients. Patients reported a negative impact of bowel urgency on their relationship with spouse/partner.</p><p><strong>Conclusions: </strong>In US and Europe, most patients reported avoiding or decreasing sexual activity due to moderate-to-severe UC or CD, with bowel urgency and bowel urgency-related accidents being common reasons. Assessing and addressing sexual health in routine clinical care should be considered when treating UC and CD.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-15"},"PeriodicalIF":2.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to colorectal cancer screening with multi-target stool DNA testing among first-time average-risk users in federally qualified health centers.","authors":"Mallik Greene, Timo Pew, Lakshya Sakthisivabalan, Jorge Zapatier, Jeffrey Arroyo, Juliana Vanessa Rincón López, Jordan J Karlitz, Martha Duarte","doi":"10.1080/03007995.2025.2529984","DOIUrl":"10.1080/03007995.2025.2529984","url":null,"abstract":"<p><strong>Introduction: </strong>Federally Qualified Health Centers (FQHC) provide healthcare services to nearly 30 million people across the United States. Despite this critical role, substantial gaps in colorectal cancer (CRC) screening persist in FQHC populations compared to the general U.S. population. This study evaluated the adherence to multi-target stool DNA (mt-sDNA) screening among average-risk patients undergoing their first CRC screening at FQHCs.</p><p><strong>Methods: </strong>Patients aged 45-75 years that received care at FQHC clinics and had a valid mt-sDNA test kit shipped between January 1 and December 31, 2023, were included. Patient adherence was defined as the completion and return of the test kit, with a valid test result obtained within 365 days of the initial shipment date. Logistic regression analysis was performed to determine patient characteristics associated with adherence.</p><p><strong>Results: </strong>A total of 264,465 patients had a mt-sDNA test kit shipped to them during the study period. The overall adherence to screening was 55.9%, with an average of 37 days from initial shipment date to valid test result. Predictors associated with increased adherence included being commercially insured, having lower social vulnerability scores, older age, female sex, digital patient outreach, living outside a metropolitan area, and living in a ZIP code with higher median household income.</p><p><strong>Conclusion: </strong>The current study found that the adherence to mt-sDNA testing in a patient population receiving care at FQHCs was higher than previously reported. This research highlighted several important predictors of improved adherence to mt-sDNA testing, including digital patient outreach as an inexpensive and increasingly utilized screening option for CRC.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-11"},"PeriodicalIF":2.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144574990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meningococcal B vaccine co-administration in older adolescents and young adults and potential missed opportunities for vaccination in the United States: a retrospective claims database analysis.","authors":"Oscar Herrera-Restrepo, Jasjit K Multani, Zifan Zhou, Queenie Paltanwale, Tosin Olaiya, Anna D Coutinho, Rajeev B Shah, Chi-Chang Chen","doi":"10.1080/03007995.2025.2522806","DOIUrl":"10.1080/03007995.2025.2522806","url":null,"abstract":"<p><strong>Background: </strong>In the United States (US), meningococcal serogroup B (MenB) vaccination is currently recommended under shared clinical decision-making for 16-23-year-olds to prevent invasive meningococcal disease; the MenB vaccine may be co-administered with other vaccines recommended for this age group.</p><p><strong>Research design and methods: </strong>A retrospective analysis of two US health insurance claims databases was conducted to estimate the proportion of commercially insured and Medicaid-insured 16-23-year-olds with potential missed opportunities for MenB vaccine series initiation <i>via</i> co-administration. Potential missed opportunities were defined as visits with healthcare providers during which other recommended vaccines (MenACWY, Tdap, HPV, influenza, and/or COVID-19) were administered, but not the initial MenB vaccine dose.</p><p><strong>Results: </strong>In 2022, 74.5% of commercially insured and 67.1% of Medicaid-insured 16-23-year-olds had potential missed opportunities for MenB vaccination initiation <i>via</i> co-administration. The proportion of missed opportunities was higher among 19-23-year-olds (versus 16-18-year-olds) and lower for visits with pediatricians (versus internists or general practitioners/family physicians). The most frequently co-administered vaccine was the MenACWY vaccine.</p><p><strong>Conclusions: </strong>Many 16-23-year-olds had potential missed opportunities for MenB series initiation <i>via</i> co-administration. Increasing awareness of the opportunity to initiate the MenB series <i>via</i> co-administration may improve meningococcal vaccination coverage in the US.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-13"},"PeriodicalIF":2.4,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of the relationship between the inclusion of industry authors and the impact and perception of peer-reviewed scientific publications.","authors":"Sanchaita Sriwal Sonar, Emma Raderschadt, Shivangi Gupta, Stefan Courtney, Rachana Patel","doi":"10.1080/03007995.2025.2527673","DOIUrl":"10.1080/03007995.2025.2527673","url":null,"abstract":"<p><strong>Objective: </strong>To assess whether pharmaceutical industry authorship affects the impact and perceived credibility of clinical publications.</p><p><strong>Methods: </strong>A PubMed search for clinical trials in four therapy areas (oncology, cardiometabolism, central nervous system and inflammation), published in peer-reviewed journals between 2018 and 2023, was performed. Industry authors were identified. Publication impact (total citations and X interactions) was analyzed for each paper. A multinational survey of 180 healthcare professionals assessed whether industry authorship affects perception of publications.</p><p><strong>Results: </strong>A weak but significant negative correlation was demonstrated between the percentage of industry authors and academic citations and X interactions (r = -0.10 and r = -0.13, respectively; both <i>p</i> < 0.0001), regardless of journal impact factor or total author number. Papers with ≥50% or lead/last authors from industry had significantly lower citations and X interactions. In the survey, 57% of respondents thought author affiliation and 24% thought industry affiliation were important factors affecting publication credibility. Over half of respondents thought publication credibility decreased due to high numbers (56%) or a majority (61%) of industry authors, and an industry author as lead/last author (57%). 68% associated high numbers of industry authors with a potential for bias.</p><p><strong>Conclusion: </strong>These analyses show that industry authorship influences the credibility and impact of scientific publications. It is essential to raise awareness of the pharmaceutical industry's commitment to good publication practices, which ensures authorship is based on merit and genuine contributions. Future research should focus on understanding and addressing how authorship dynamics shape the perception and trustworthiness of scientific work, ensuring a balance that fosters both innovation and public confidence.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-10"},"PeriodicalIF":2.4,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world clinical outcomes of patients with moderate-to-severe rheumatoid arthritis initiating upadacitinib in the United Kingdom: final analysis from a prospective observational cohort study (ENDEAVOUR).","authors":"James Taylor, Srinivasan Srirangan, Marwan Bukhari, Syed Bilgrami, Muhammad K Nisar, Stephen McDonald, Nicola Goodson, Andrew Allard, Alison Kinder, Michael Green, Laura Hunt, Sabrina Raizada, Bruce Kirkham, Eleri Thomas, Rachel Horsfall, Terri-Leigh Niblock, Victoria Burton, James Galloway","doi":"10.1080/03007995.2025.2515280","DOIUrl":"10.1080/03007995.2025.2515280","url":null,"abstract":"<p><strong>Objective: </strong>Upadacitinib is recommended by National Institute for Health and Care Excellence in the UK in adults with moderate-to-severe rheumatoid arthritis (RA). This observational study assessed real-world clinical outcomes and patient-reported outcomes (PROs) in patients receiving upadacitinib for 6 months in the UK.</p><p><strong>Methods: </strong>Patients from 14 centres in whom the decision to initiate upadacitinib had already been made were enrolled. Baseline data were retrospectively collected from patient records. Clinician-reported data were collected at routine clinic visits 3 and 6 months after upadacitinib initiation. Patient-reported data were collected directly from patients using an app (electronic PROs, ePROs). The primary end-point was proportion of patients achieving clinical remission (DAS28 CRP <2.6) after 6 months of upadacitinib.</p><p><strong>Results: </strong>Data are available for 63 patients at all three datapoints and for 53 patients for the primary end-point. At 6 months, 40% (21/53) of patients achieved clinical remission and 21% (11/53) achieved low disease activity. Response was seen at 3 months for all efficacy end-points. ePROs allowed the capture of early patient-reported data which demonstrated clinically important improvements in pain and fatigue within 10 days and other PROs within 2 months. Improvements were also seen in metrics of activity, work and quality of life (QOL).</p><p><strong>Conclusion: </strong>Patients in ENDEAVOUR showed similar early effectiveness with upadacitinib to that observed in clinical trials. Use of ePROs demonstrated rapid onset of action and meaningful improvements in QOL providing a potential opportunity to reduce outpatient visits for early responders, thus reducing the burden on rheumatology services.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-13"},"PeriodicalIF":2.4,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health care provider- and patient-reported outcomes for bictegravir/emtricitabine/tenofovir alafenamide versus other antiretroviral regimens: an observational survey in the United States (July 2021-March 2022).","authors":"Amy Colson, Megan Chen, Fritha Hennessy, Joshua Gruber, Woodie Zachry, Seojin Park, Tim Holbrook","doi":"10.1080/03007995.2025.2517692","DOIUrl":"10.1080/03007995.2025.2517692","url":null,"abstract":"<p><strong>Objective: </strong>This study compared outcomes reported by health care providers (HCPs) and people with HIV (PWH) for individuals prescribed bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus other antiretroviral therapy (ART) regimens.</p><p><strong>Methods: </strong>Data were from the Adelphi Real World HIV Disease Specific Programme, an observational, cross-sectional survey of HCPs and PWH conducted from July 2021-March 2022 in the United States. PWH were aged ≥18 years with confirmed HIV and a current ART prescription. Outcomes included HCP- and PWH-reported adherence, treatment satisfaction, quality of life (QoL), and health care resource utilization (HCRU). Subgroups for the primary analysis were based on ART regimen. Comparisons between subgroups were performed using appropriate statistical tests.</p><p><strong>Results: </strong>Sixty HCPs provided data for 600 PWH, and 249 PWH reported their experiences. Overall, 264 PWH were prescribed B/F/TAF, 281 were prescribed other single-tablet regimens or a long-acting injectable (STRs/LAI), and 55 were prescribed a multi-tablet regimen. Common HCP-reported reasons for choice of ART were viral potency and tolerability. High treatment satisfaction was reported for B/F/TAF by HCPs (61% \"very satisfied\" with B/F/TAF vs 53% with other STRs/LAI; <i>p</i> = 0.0223) and PWH (57% vs 52%, respectively; <i>p</i> = 0.3170). PWH receiving B/F/TAF reported significantly higher QoL and lower activity impairment versus PWH receiving other STRs/LAI. Adherence rates and HCRU were generally similar between groups.</p><p><strong>Conclusion: </strong>Positive HCP- and PWH-reported outcomes were seen across ART regimens. However, differences observed, including HCP-reported treatment satisfaction and PWH-reported QoL, favored B/F/TAF compared with other STRs/LAI. Findings support continued use of B/F/TAF for HIV treatment in the United States.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-13"},"PeriodicalIF":2.4,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new strategy for the selection of patients with hip osteoarthritis to avoid inappropriate total hip replacement based on imaging and clinical characteristics.","authors":"Kazuo Hayashi, Yves Henrotin, Toshiharu Tsunoda, Shoji Tokunaga","doi":"10.1080/03007995.2025.2521097","DOIUrl":"10.1080/03007995.2025.2521097","url":null,"abstract":"<p><strong>Background: </strong>Total hip replacement (THR) is extremely common and generally results in excellent patient satisfaction. However, 36% of patients with hip osteoarthritis who undergo THR reportedly experience long-term postoperative pain. Furthermore, only 20% of patients attempt exercise before surgery, despite the recommendation for 3-6 months of conservative treatment before surgery. Despite these facts, the number of THRs performed annually is currently increasing.</p><p><strong>Objectives: </strong>To propose and discuss a new strategy based on clinical and radiological characteristics for selecting candidates for Pericapsular Soft Tissue and Pelvic Realignment (PSTP-R) therapies to avoid inappropriate THR.</p><p><strong>Methods: </strong>The PubMed electronic database was searched to identify publications reporting data from clinical studies on the diagnosis and treatment of osteoarthritis in humans published between 1995 and 2023. This narrative review summarizes the findings of these previous studies.</p><p><strong>Results: </strong>A previous study reported that PSTP-R therapy comprising pelvic realignment, muscle strengthening, and stretching was effective for patients with a Harris Hip Score (HHS) below 60 points, even those with complete loss of cartilage on radiography. A post hoc study showed that the risk of discontinuation of PSTP-R therapy increased with increasing frequency of pain in the buttock at baseline. Cartilage loss was not a risk factor for withdrawal from PSTP-R therapy.</p><p><strong>Conclusion: </strong>Patients should be better informed regarding the benefits of THR and the possibility of persistent postoperative pain. If the patient has complete loss of cartilage on radiography but no buttock pain, PSTP-R therapy might improve their pain and avoid THR.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-12"},"PeriodicalIF":2.4,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}